放射性131Ⅰ治疗分化型甲状腺癌肺转移的疗效及其主要预后因素的系统评价

Objective To assess the effect of radioiodine-131 (131Ⅰ) on treatment of pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors. Methods Five databases were retrieved and all published studies which analyzed the effect of 131Ⅰ on pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors were systematically reviewed. The data about the impact of 131Ⅰ treatment and the main prognostic factors on the 5-yr and 10-yr survival rates of the patients were abstracted. RevMan 4.2 software was used to statistically analyze. Results Eleven retrospective cohort studies were included. The pooled results suggested that the 5-yr survival rates of the patients who received 131Ⅰ therapy and who did not received 131Ⅰl therapy were 74.9% and 27.1% , respectively ;The lO-yr survival rates(P<0.01)of the two groups were 60.8% % 12.2% , respectively;The difference between them had statistical significance (P<0.01). The 5-yr and 10-yr survival rates of the patients only with pulmonary metastases were higher than those of the patients with multiple metastases (P<0.01). The 5-yr (P = 0.01) and 10-yr (P = 0. 002)surviv10al rates of the patients only with papillary thyroid carcinoma were higher than those of the patients with follicular thyroid carcinoma. The 5-yr and 10-yr survival rates of male and female patients were similar(P>0.05). Conclusions 131Ⅰ treatment increases the 5-yr and 10-yr survival rates of patients with pulmonary metastases from differentiated thyroid carcinoma. The extent of metastases and the histologie type of differentiated thyroid carcinoma are two main predicting factors of prognosis. The 5-yr and 10-yr survival rates of patients are not influenced by gender.     

减轻131Ⅰ致分化型甲状腺癌患者唾液腺损伤的措施

131Ⅰ治疗可显著改善分化型甲状腺癌(differentiated thyroid carcinoma,DTC)患者的预后,但131Ⅰ可致DTC患者唾液腺的损伤,现将减轻131Ⅰ致DTC患者唾液腺损伤的措施介绍如下.     

放射性131Ⅰ治疗分化型甲状腺癌肺转移的疗效及其主要预后因素的系统评价

Objective To assess the effect of radioiodine-131 (131Ⅰ) on treatment of pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors. Methods Five databases were retrieved and all published studies which analyzed the effect of 131Ⅰ on pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors were systematically reviewed. The data about the impact of 131Ⅰ treatment and the main prognostic factors on the 5-yr and 10-yr survival rates of the patients were abstracted. RevMan 4.2 software was used to statistically analyze. Results Eleven retrospective cohort studies were included. The pooled results suggested that the 5-yr survival rates of the patients who received 131Ⅰ therapy and who did not received 131Ⅰl therapy were 74.9% and 27.1% , respectively ;The lO-yr survival rates(P<0.01)of the two groups were 60.8% % 12.2% , respectively;The difference between them had statistical significance (P<0.01). The 5-yr and 10-yr survival rates of the patients only with pulmonary metastases were higher than those of the patients with multiple metastases (P<0.01). The 5-yr (P = 0.01) and 10-yr (P = 0. 002)surviv10al rates of the patients only with papillary thyroid carcinoma were higher than those of the patients with follicular thyroid carcinoma. The 5-yr and 10-yr survival rates of male and female patients were similar(P>0.05). Conclusions 131Ⅰ treatment increases the 5-yr and 10-yr survival rates of patients with pulmonary metastases from differentiated thyroid carcinoma. The extent of metastases and the histologie type of differentiated thyroid carcinoma are two main predicting factors of prognosis. The 5-yr and 10-yr survival rates of patients are not influenced by gender.     

TGF-β与MAPK细胞内信号转导通路的交互调节及其在心血管疾病中的作用

TGF-β/Smad和MAPK细胞内信号转导通路在调节细胞的增殖、分化、凋亡等生物学过程中均发挥着重要的作用。这两条通路可在膜受体、细胞内信号分子和核内基因水平等多个层次发生复杂的交互调节关系,使细胞对外界刺激信号产生相应的生物学效应。它们通过对血管平滑肌细胞(vascular smooth muscle cell,VSMC)和内皮细胞的增殖、分化、迁移等细胞生物学行为的调节而抑制或促进高血压、动脉粥样硬化、心肌病等心血管疾病的进展。     

放射性131Ⅰ治疗分化型甲状腺癌肺转移的疗效及其主要预后因素的系统评价

Objective To assess the effect of radioiodine-131 (131Ⅰ) on treatment of pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors. Methods Five databases were retrieved and all published studies which analyzed the effect of 131Ⅰ on pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors were systematically reviewed. The data about the impact of 131Ⅰ treatment and the main prognostic factors on the 5-yr and 10-yr survival rates of the patients were abstracted. RevMan 4.2 software was used to statistically analyze. Results Eleven retrospective cohort studies were included. The pooled results suggested that the 5-yr survival rates of the patients who received 131Ⅰ therapy and who did not received 131Ⅰl therapy were 74.9% and 27.1% , respectively ;The lO-yr survival rates(P<0.01)of the two groups were 60.8% % 12.2% , respectively;The difference between them had statistical significance (P<0.01). The 5-yr and 10-yr survival rates of the patients only with pulmonary metastases were higher than those of the patients with multiple metastases (P<0.01). The 5-yr (P = 0.01) and 10-yr (P = 0. 002)surviv10al rates of the patients only with papillary thyroid carcinoma were higher than those of the patients with follicular thyroid carcinoma. The 5-yr and 10-yr survival rates of male and female patients were similar(P>0.05). Conclusions 131Ⅰ treatment increases the 5-yr and 10-yr survival rates of patients with pulmonary metastases from differentiated thyroid carcinoma. The extent of metastases and the histologie type of differentiated thyroid carcinoma are two main predicting factors of prognosis. The 5-yr and 10-yr survival rates of patients are not influenced by gender.     

放射性131Ⅰ治疗分化型甲状腺癌肺转移的疗效及其主要预后因素的系统评价

Objective To assess the effect of radioiodine-131 (131Ⅰ) on treatment of pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors. Methods Five databases were retrieved and all published studies which analyzed the effect of 131Ⅰ on pulmonary metastases from differentiated thyroid carcinoma and the main prognostic factors were systematically reviewed. The data about the impact of 131Ⅰ treatment and the main prognostic factors on the 5-yr and 10-yr survival rates of the patients were abstracted. RevMan 4.2 software was used to statistically analyze. Results Eleven retrospective cohort studies were included. The pooled results suggested that the 5-yr survival rates of the patients who received 131Ⅰ therapy and who did not received 131Ⅰl therapy were 74.9% and 27.1% , respectively ;The lO-yr survival rates(P<0.01)of the two groups were 60.8% % 12.2% , respectively;The difference between them had statistical significance (P<0.01). The 5-yr and 10-yr survival rates of the patients only with pulmonary metastases were higher than those of the patients with multiple metastases (P<0.01). The 5-yr (P = 0.01) and 10-yr (P = 0. 002)surviv10al rates of the patients only with papillary thyroid carcinoma were higher than those of the patients with follicular thyroid carcinoma. The 5-yr and 10-yr survival rates of male and female patients were similar(P>0.05). Conclusions 131Ⅰ treatment increases the 5-yr and 10-yr survival rates of patients with pulmonary metastases from differentiated thyroid carcinoma. The extent of metastases and the histologie type of differentiated thyroid carcinoma are two main predicting factors of prognosis. The 5-yr and 10-yr survival rates of patients are not influenced by gender.     

18F-FDG符合线路显像诊断鼻咽癌的价值

目的 探讨18F-FDG符合线路显像在鼻咽癌诊断中的价值.方法 回顾性分析45例首发鼻咽癌患者资料,均经病理检查证实,治疗前行18F-FDG符合线路显像,计算鼻咽部病灶的放射性计数与全小脑放射性平均计数比(即T/NT)值及肿瘤体积.采用配对x2检验比较18F-FDG符合线路显像与EB病毒相关抗体检测方法阳性率差异;对T/NT值与肿瘤体积行Pearson相关分析;使用ROC曲线确定T/NT值及肿瘤体积的最佳界值;并采用t检验和秩和检验对比分析不同分组方法组间T/NT值及肿瘤体积的差异.结果 18F-FDG符合线路显像阳性率为97.78％ (44/45),EB病毒相关抗体总阳性率为95.56％ (43/45),两者差异无统计学意义(x2=1.33,P＞0.05).鼻咽部原发病灶T/NT值为2.439±1.119,肿瘤体积为(7.311 ±8.280) cm3,两者呈正相关(r=0.463,P＜0.05).ROC曲线确定T/NT值的最佳界值为2.396,肿瘤体积的最佳界值为7.348 cm3.首发症状有无涕血组间、有无面部麻木组间及各病理类型组间T/NT值差异均有统计学意义(2.847±1.254与2.082±0.863、2.855±1.261与2.134±0.913、2.266±0.997与2.971±1.351,t=- 2.409、-2.225和-2.018,P均＜0.05);首发症状有无面部麻木组间肿瘤体积差异有统计学意义(t=-2.684,P＜0.05).按临床分期及T分期分组,组间T/NT值及肿瘤体积差异均无统计学意义(临床分期H=5.895和1.855,P均＞0.05,T分期H=4.756和0.270,P均＞0.05).结论 18F-FDG符合线路显像诊断鼻咽癌有一定价值,半定量指标T/NT值与肿瘤体积有较好的相关性,T/NT界值的确定需长期大样本研究进一步验证.     

减轻131Ⅰ致分化型甲状腺癌患者唾液腺损伤的措施

131Ⅰ治疗可显著改善分化型甲状腺癌(differentiated thyroid carcinoma,DTC)患者的预后,但131Ⅰ可致DTC患者唾液腺的损伤,现将减轻131Ⅰ致DTC患者唾液腺损伤的措施介绍如下.     

Smad通路参与ERK通路诱导血管平滑肌细胞增殖的过程

目的： 探讨Smad通路是否参与细胞外信号调节激酶(ERK)通路诱导血管平滑肌细胞（VSMCs）增殖的过程及其可能机制。方法：将人脐动脉平滑肌细胞（hUASMCs）分为对照组、血小板源性生长因子（PDGF）组、ERK阻断剂组和PDGF+ERK阻断剂组。用MTT法测hUASMCs的增殖活性(A值)，用免疫组化法测hUASMCs内细胞核增殖抗原（PCNA）、磷酸化ERK和磷酸化Smad蛋白的表达，用RT-PCR法测hUASMCs内Smad2/3 mRNA的表达。结果：PDGF组hUASMCs的增殖活性(A值)及hUASMCs内的PCNA、磷酸化ERK和磷酸化Smad2/3蛋白的表达都明显高于其它各组(P<0.01)；各组hUASMCs内Smad2/3 mRNA的表达没有差异。结论： Smad通路可在蛋白水平参与ERK通路诱导VSMCs的增殖过程。     

孕产妇梅毒护理体会

目的：探讨预防发生先天梅毒的有效措臆，旨在降低先天梅毒的发生率，提高围产儿的生存质量。加强性道德、性卫生的宣传教育及性病知识的普及教育，切实抓好健康教育工作及孕前检查，加强孕妇学校建设，做好孕期管理和监测。